Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 8/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.36 |
| ▸ | MAPT | P10636 | 6/20 | 0.34 |
| ▸ | HTT | P42858 | 5/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL751161 | 0.86 | TSHR (0.36) | ALOX15TSHRHSD17B10LMNASMN1; SMN2 | |
| SCHEMBL755677 | 0.71 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL754936 | 0.70 | L3MBTL1 (0.33) | HSD17B10SMN1; SMN2ALDH1A1HPGDKDM4E | |
| SCHEMBL754183 | 0.67 | SLC2A1 (0.35) | MAPTHTTGAAHPGDKMT2A | |
| SCHEMBL7890083 | 0.67 | SPR (0.36) | HSD17B10HPGDKDM4ERAB9A | |
| SCHEMBL754096 | 0.66 | SLC2A1 (0.34) | MAPTHTTGAAKMT2AKDM4E | |
| SCHEMBL11892543 | 0.66 | SMN1; SMN2 (0.41) | ALOX15TSHRHSD17B10LMNASMN1; SMN2 | |
| SCHEMBL47767 | 0.64 | — | — | |
| SCHEMBL11892542 | 0.64 | TSHR (0.37) | ALOX15TSHRHSD17B10LMNASMN1; SMN2 | |
| SCHEMBL30259766 | 0.62 | SRC (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | claimed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | claimed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | ALOX15 4078/4885TSHR 3459/4885HSD17B10 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.